In recent years a distinct clinical syndrome has been delineated, consisting typically of one or more of thrombosis, thrombocytopenia, and recurrent fetal loss, together with raised levels of antibodies to negatively charged phospholipids (reviewed in refs 1 and 2). Although these clinical features had been associated with the presence of the lupus anticoagulant (subsequently shown to be mediated by antiphospholipid antibodies), it was the development of a solid phase radioimmunoassay for anticardiolipin antibodies which allowed the easy and sensitive detection of antiphospholipid antibodies and made possible a large number of studies on the clinical and other associations of these antibodies.3
Accepted for publication 19 Discussion This paper reports the clinical and serological findings for a series of 20 patients with raised anticardiolipin antibodies, in whom a diagnosis of SLE was excluded according to the American Rheumatism Association revised criteria and in whom no other substantive diagnosis was possible. They may be regarded as having a primary antiphospholipid syndrome.
The composition of the patient group is not random as it consists chiefly of patients seen in the rheumatology unit at the Hammersmith Hospital, or referred to the department of obstetrics and gynaecology because of obstetric problems. The former were referred either because of a clinical problem which suggested a connective tissue disease, or because of the presence of raised anticardiolipin antibodies; the latter were identified by the routine anticardiolipin antibody testing of women with a history of multiple abortions. As a consequence there is likely to be an ascertainment bias; patients are currently tested for anticardiolipin antibody levels because of a clinical suspicion that these may be raised. Thus although a number of studies have shown an extremely low incidence of raised anticardiolipin antibody titres among normal individuals andpatients with awide range ofmedical conditions, it is probable that our patient cohort is not wholly representative of all individuals with raised titres, in that it may exclude some otherwise normal individuals and patients with other as yet unassociated conditions. It is likely, therefore, that the manifestations described here overestimate the severity of the clinical syndrome associated with these autoantibodies.
Nine out of 20 (47%) of our patients had a positive antinuclear antibody test at some stage in their illness; six of these (67%) were individuals with multiple abortions. In most cases the test was positive at a low titre. One patient with a negative antinuclear antibody test had antibodies to the extractable nuclear antigen Ro. These findings suggest that many of these patients have a condition which is related to SLE. The sex ratio (nine women to one man) and age range of our patients (17-53 years, median 30) are also similar to those found in SLE. There is also clearly an overlap between the clinical features seen in some of our patients-for example, arthralgias, Raynaud's phenomenon, migraine, livedo reticularis, and vasculitic rash-and lupus.
Our patients are, however, more striking for the presence of clinical features previously associated with raised anticardiolipin antibody levels: thrombosis (both venous and arterial),3 fetal loss,'17 and thrombocytopenia. 18 In those individuals with venous thrombosis and fetal loss there was a relatively high incidence of raised anticardiolipin antibodies of the IgG class, a finding which accords with previous reports. In addition, some of our patients had features described but less clearly associated with raised serum anticardiolipin antibodies: livedo reticularis,19 neurological disorders other than stroke,3 and aortic and mitral valve disease.20 Thus it appears that our patients display a range of clinical features similar to those of subjects with raised anticardiolipin antibodies in the presence of other disorders; and, although some have features of SLE, others do not. At least seven of our patients had features of the antiphospholipid syndrome but no other abnormalities.
These findings are consistent with the idea that the antiphospholipid syndrome may exist as a distinct clinical entity.' It seems to show considerable overlap with other connective tissue disorders but does not appear to be merely a subset. It is possible that the clinical abnormalities are due to pathophysiological activities of antiphospholipid antibodies themselves, though no direct causal link has been established. There is, however, considerable in vitro evidence for their ability to interfere with clotting mechanisms,21 22 and this contrasts with other non-organ specific autoantibodies such as anti-DNA antibodies, which are thought to cause tissue damage by immune complex formation. It may be that further study of primary cases of the antiphospholipid syndrome, such as those described in this report, will lead to a better understanding of its pathogenesis.
